# FDA drug recall: Dabigatran Etexilate Capsules, 150 mg, 60-count (6x10) blister pack further packaged in a carton, Rx only, Manufactured 

> recall · VERIFIED · 2026-07-16

Firm: Ascend Laboratories, LLC · Class III · Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability

- Company: Ascend Laboratories, LLC
- Sector: therapeutics
- Primary source: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.